Zhijun Miao

Zhijun Miao

Auto-generated profile, based on publicly available information

Zhijun Miao


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2020 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
YLYuxin Lin
Yuxin Lin
XZXiaojun Zhao
Xiaojun Zhao
ZMZhijun Miao
Zhijun Miao
ZLZhixin Ling
Zhixin Ling
WXWei Xuedong
Wei Xuedong
BSBairong Shen
Bairong Shen
Prostate cancer (PCa) is a common malignant tumor with increasing incidence and high heterogeneity among males worldwide. In the era of big data and artificial intelligence, the paradigm of biomarker discovery is shifting from traditional experimental and small data-based identification toward big data-driven and systems-level screening. Complex interactions between genetic factors and environmental effects provide opportunities for systems modeling of PCa genesis and evolution. We hereby review the current research frontiers in informatics for PCa clinical translation. First, the heterogeneity and complexity in PCa development and clinical theranostics are introduced to raise the concern for PCa systems biology studies. Then biomarkers and risk factors ranging from molecular alternations to clinical phenotype and lifestyle changes are explicated for PCa personalized management. Methodologies and applications for multi-dimensional data integration and computational modeling are discussed. The future perspectives and challenges for PCa systems medicine and holistic healthcare are finally provided.

17 September 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ZMZhijun Miao
Zhijun Miao
XSXue Song
Xue Song
安徐安安 徐
安安 徐
CYChang Yao
Chang Yao
PLPeng Li
Peng Li
ASand Gang Shen
and Gang Shen
Background: Activating the cytosolic innate immune sensor, the cGAS-STING pathway, holds great promise for enhancing antitumor immunity, particularly in combination with immune checkpoint inhibitors (ICIs). However, the clinical application of STING agonists is often hindered by poor tumor accumulation, limited cellular uptake, and rapid clearance. To address these challenges, we developed a human serum albumin (HSA)-based nanoreactor system for the efficient delivery of the STING agonist SR-717, aiming to improve its antitumor efficacy. Methods: Using a biomineralization technique, we encapsulated SR-717 within HSA nanocages to form SH-NPs. These nanoparticles were characterized in terms of size, stability, and cellular uptake, and their ability to activate the STING pathway was assessed in both in vitro and in vivo models, including freshly isolated human renal tumor tissues. In vivo antitumor efficacy was evaluated in a murine renal tumor model, and immune responses were measured. Results: SH-NPs exhibited enhanced stability, efficient cellular uptake, and superior tumor accumulation compared to free SR-717. They robustly activated the STING pathway, as evidenced by increased phosphorylation of TBK1 and IRF3, along with elevated IFN-β production. Additionally, SH-NPs reshaped the immunosuppressive tumor microenvironment, promoting T-cell-mediated immunity and improving the therapeutic efficacy of checkpoint blockade in murine models. The validation in human renal tumor tissues further highlighted their potential for clinical translation. Importantly, SH-NPs were well tolerated with minimal systemic toxicity. Conclusions: This study underscores the potential of HSA-based nanoparticles for the targeted delivery of STING agonists, effectively enhancing antitumor immunity and improving cancer immunotherapy outcomes. SH-NPs offer a promising solution to the limitations of current STING agonists in clinical settings.

30 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ZMZhijun Miao
Zhijun Miao
XSXue Song
Xue Song
安徐安安 徐
安安 徐
CYChang Yao
Chang Yao
PLPeng Li
Peng Li
ASand Gang Shen
and Gang Shen
Activating the cytosolic innate immune sensor cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway via natural and synthetic agonists holds great potential for priming robust antitumor immunity. However, the effectiveness of STING agonists is often impeded by the insufficient tumor accumulation, poor cellular entry, and rapid clearance, thus leading to difficulty of their clinic translation. Herein, we apply the human serum albumin as the single-molecule nanoreactor to encapsulate SR-717 (SH-NPs) for enhanced targeting delivery efficiency and biological potency. SH-NPs with rational size distribution exhibited superior serum stability, considerable cellular uptake and abundant tumor accumulation, thus increasing the STING signaling including phosphorylation of STING-associated proteins (TBK1, IRF3), and cytokines secretion inside tumor region. Subsequently, SH-NPs remarkably reshape the immunosuppressive tumor microenvironment into an immunogenic one that boosts antitumor T-cell immunity and improves the therapeutic efficacy of checkpoint blockade against murine tumors. We also validate SH-NPs in freshly isolated human renal tumor tissues to highlight their clinic translation capability. These findings pave the way towards targeted STING agonist delivery for reinvigorated immunotherapy of intractable cancers.

15 May 2026 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
JYJiajian Yang
Jiajian Yang
ZYZhengyao You
Zhengyao You
HMHaojie Mo
Haojie Mo
JPJinxian Pu
Jinxian Pu
ASand Gang Shen
and Gang Shen
ZMZhijun Miao
Zhijun Miao
Background: Bladder cancer (BLCA) exhibits a poor prognosis, highlighting the urgent need for reliable prognostic genes. Although succinylation is linked to tumor progression, its role in BLCA remains understudied. This study aimed to identify and validate prognostic succinylation-related genes (SRGs) in BLCA and elucidate their impact on the tumor microenvironment (TME). Methods: SRGs were initially identified through transcriptomic sequencing of 15 paired BLCA and adjacent normal tissues (Soochow-BLCA cohort) and further refined by integrating single-cell and bulk transcriptomic data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. A prognostic risk model was developed using LASSO and multivariable Cox regression, incorporating clinical factors for nomogram construction. Mechanistic insights were obtained through functional enrichment, immune profiling, somatic mutation, and drug sensitivity analyses. The Scissor algorithm mapped bulk transcriptome risk signatures to single-cell resolution, enabling identification of high-risk cell subpopulations. Pseudotime and cell-cell communication analyses characterized dynamic expression patterns of the core genes. Finally, the expression profiles and functional roles of the core genes were validated using RT-qPCR and CCK-8 proliferation assays in vitro . Results: KCTD16, CD3D and GSDMB were identified as prognostic genes. The risk score derived from these genes, in combination with age and N stage, was incorporated into a risk model that exhibited robust predictive accuracy (AUC > 0.7). Expression of these genes differed significantly between non-muscle-invasive and muscle-invasive subtypes. The high-risk group displayed enhanced immune evasion (higher TIDE score, p < 0.001), while the TME appeared to be in an “inflamed yet dysfunctional” state. Single-cell analysis indicated epithelial cells as key subpopulations, with additional involvement of T cells and fibroblasts. Scissor + cells were correlated with the high-risk phenotype and exhibited pseudotime-dependent expression patterns. RT-qPCR revealed significant upregulation of GSDMB and downregulation of KCTD16 and CD3D in BLCA ( p < 0.05). Functionally, knockdown of GSDMB and KCTD16 significantly promoted T24 cell proliferation, supporting their tumor-suppressive roles. Conclusions: The succinylation-related prognostic model accurately predicts outcomes in BLCA, reveals links to immune escape and TME, and highlights the pivotal role of epithelial cells, offering potential targets for individualized therapy.

3 November 2026 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JSJiale Sun
Jiale Sun
HMHaojie Mo
Haojie Mo
HZHaoyang Zhang
Haoyang Zhang
PLPeng Li
Peng Li
ZMZhijun Miao
Zhijun Miao
ASand Gang Shen
and Gang Shen
Purpose: As one of the most common cancers, prostate cancer is partially treated with androgen deprivation therapy. Following treatment failure, patients progress to castration-resistant prostate cancer (CRPC), which is associated with poor prognosis. This study aims to elucidate the dynamic changes in the tumor microenvironment, genetic risk architecture, and therapeutic targets across prostate cancer progression through omics analysis. Materials and methods: Tissues were collected from patients in three groups: benign prostatic hyperplasia (BPH, n = 3), treatment-naive prostate cancer (PCa, n = 4), and CRPC ( n = 3) for scRNA-seq analysis. Publicly available spatial transcriptomics data (GSE278936, 10x Visium) from 10 representative samples spanning the benign-to-advanced prostate-disease spectrum (BPH, PCa, Neoadjuvant, CRPC, Metastatic) were analyzed. gsMap was used to map GWAS genetic risk signals onto spatial niches. Geneformer was fine-tuned for virtual perturbation of key CRPC genes (LAS1L, IL6ST, TNFAIP8). Results: We report that inherited prostate-cancer genetic risk undergoes a systematic spatial redistribution as disease progresses. By integrating scRNA-seq (10 patient samples) with spatial transcriptomics and gsMap genetic-risk mapping (10 samples from GSE278936), we found that genetic-risk enrichment is concentrated in epithelial niches in localized disease but shifts to endothelial, fibroblast, and Treg/neutrophil niches in CRPC. This genetic redistribution was accompanied by a tumor-microenvironment shift from immune surveillance toward Treg-mediated suppression and by the emergence of a metabolically active CRPC2 tumor-cell state. Virtual perturbation of LAS1L altered the malignant transcriptional state, although it did not reverse it. This nominates LAS1L as a hypothesis-generating, spatially risk-associated candidate whose causal role requires experimental validation. Together, these multi-layered analyses indicate that the cell types carrying inherited disease risk are remodeled during progression to CRPC, providing a spatial-genetic framework for studying the advanced-disease microenvironment. Conclusion: In conclusion, this study delineates the dynamic shifts in the immune microenvironment during prostate cancer progression, characterized by a transition from immune surveillance to immune suppression. This study highlights the redistribution of germline genetic risk across cellular compartments as a key feature of advanced prostate cancer, providing a multi‑omics spatial resource for understanding microenvironmental remodeling in CRPC. The predicted association between LAS1L and ETV7 may provide novel insights into the tumor-immune interface in advanced prostate cancer.